Targeting the extrinsic apoptosis pathway in cancer
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2008/06/01
-
Journal
-
Indian UGC (journal)
-
Refrences30
-
Citations293
-
Avi Ashkenazi
Cite
Ashkenazi, Avi. “Targeting the Extrinsic Apoptosis Pathway in Cancer”. Cytokine &Amp; Growth Factor Reviews, vol. 19, no. 3-4, 2008, pp. 325-31, https://doi.org/10.1016/j.cytogfr.2008.04.001.
Ashkenazi, A. (2008). Targeting the extrinsic apoptosis pathway in cancer. Cytokine &Amp; Growth Factor Reviews, 19(3-4), 325-331. https://doi.org/10.1016/j.cytogfr.2008.04.001
Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine & Growth Factor Reviews. 2008;19(3-4):325-31.
Journal Categories
Science
Biology (General)
Science
Biology (General)
Cytology
Science
Biology (General)
Genetics
You May Also Like
- LPS/TLR4 signal transduction pathway
- T cell subsets and their signature cytokines in autoimmune and inflammatory diseases
- IDENTIFICATION OF POLYMORPHISMS WITHIN THE VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENE: CORRELATION WITH VARIATION IN VEGF PROTEIN PRODUCTION
- Estrogen receptors regulate innate immune cells and signaling pathways
- A comprehensive summary of LL-37, the factotum human cathelicidin peptide
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer | Journal of Clinical Oncology |
| 11 | 2007 |
A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma | Journal of Clinical Oncology |
| 36 | 2007 |
| Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 | Cell Death & Differentiation |
| 106 | 2008 |
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts | Blood Journal |
| 68 | 2007 |
| Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL | Nature Medicine |
| 425 | 2007 |
Refrences Analysis
The category
Medicine: Medicine (General) 19
is the most frequently represented among the references in this article. It primarily includes studies from Nature Medicine The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Cobalt oxide nanoparticles functionalized with glucose and conjugated to Ellagic acid (Co3O4@Glu-Ellagic acid NPs) induce apoptotic genes in HepG2, liver cancer cell line | Gene Reports | 2024 | ||
| Preparation of polypeptide-metal complexes-coated Hosenkoside A and its inhibitory effect in cervical cancer | International Journal of Biological Macromolecules |
| 2024 | |
A novel approach combining network pharmacology and experimental validation to study the protective effect of ginsenoside Rb1 against cantharidin‐induced hepatotoxicity in mice | Basic & Clinical Pharmacology & Toxicology |
| 2024 | |
Knockdown of EIF4G1 in NSCLC induces CXCL8 secretion | Frontiers in Pharmacology |
| 2024 | |
Anticancer activities of natural abietic acid | Frontiers in Pharmacology |
| 2024 |
Citations Analysis
The category
Medicine: Medicine (General) 88
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Tumor resistance to apoptosis and was published in 2008. The most recent citation comes from a 2024 study titled Anticancer activities of natural abietic acid. This article reached its peak citation in 2010, with 29 citations. It has been cited in 184 different journals, 17% of which are open access. Among related journals, the Oncotarget cited this research the most, with 10 citations. The chart below illustrates the annual citation trends for this article.